These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26845343)

  • 21. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
    Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics and pharmacokinetics of fluticasone furoate/vilanterol in healthy Chinese subjects.
    Chen X; Zheng X; Jiang J; Hu P; Wu K; Zhuang L; Liu L; Du X; Kempsford R; Allen A
    Pharmacotherapy; 2015 Jun; 35(6):586-99. PubMed ID: 26059225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device.
    Kosoglou T; Hubbell J; Johnson-Levonas AO; Yunan M; Kantesaria BS; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):222-8. PubMed ID: 27128612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma.
    Blair HA
    Drugs; 2021 Apr; 81(6):709-719. PubMed ID: 33871819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O; Mucsi J; Kolosa N; Bandelli L; Sen B; Satlin LC; D'Andrea P
    Respir Med; 2020 Jan; 161():105809. PubMed ID: 32056721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of intranasal mometasone in the fixed-dose combination GSP301 versus two monotherapy intranasal mometasone formulations.
    Patel P; Salapatek AM; Talluri RS; Tantry SK
    Allergy Asthma Proc; 2018 May; 39(3):232-239. PubMed ID: 29669668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
    Zou C; Yang Q; Yang S; Zhang X; Yang X; Huang Z; Pei Q; Huang J; Yang G
    Pulm Pharmacol Ther; 2020 Apr; 61():101902. PubMed ID: 32045673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of intranasal olopatadine in the fixed-dose combination GSP301 versus two monotherapy intranasal olopatadine formulations.
    Patel P; Salapatek AM; Talluri RS; Tantry SK
    Allergy Asthma Proc; 2018 May; 39(3):224-231. PubMed ID: 29669667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects.
    Kosoglou T; Hubbell J; Kantesaria B; Hanson ME; Cutler DL
    Clin Pharmacol Drug Dev; 2014 May; 3(3):229-34. PubMed ID: 27128613
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative clinical pharmacology of mometasone furoate, fluticasone propionate and fluticasone furoate.
    Daley-Yates PT; Deans A; Mehta R; Sousa AR
    Pulm Pharmacol Ther; 2022 Dec; 77():102171. PubMed ID: 36243386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H; D'Andrea P; Tanase AM; Pethe A; Tanaka Y; Matsuo K; Hosoe M; Nakamura Y
    J Asthma; 2023 Feb; 60(2):403-411. PubMed ID: 35348408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma.
    de Llano LP; Naval E; Mejía N; Domínguez-Ortega J
    Expert Rev Respir Med; 2022 Jan; 16(1):1-15. PubMed ID: 34783265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained 24-hour efficacy of once daily indacaterol (300 μg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study.
    Laforce C; Aumann J; de Teresa Parreño L; Iqbal A; Young D; Owen R; Higgins M; Kramer B;
    Pulm Pharmacol Ther; 2011 Feb; 24(1):162-8. PubMed ID: 20619353
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma.
    Sharpe M; Jarvis B
    Drugs; 2001; 61(9):1325-50. PubMed ID: 11511026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A new once-daily long-acting β
    Brusselle G
    Lancet Respir Med; 2020 Oct; 8(10):936-937. PubMed ID: 32653076
    [No Abstract]   [Full Text] [Related]  

  • 37. Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma.
    Pelaia C; Crimi C; Crimi N; Ricciardi L; Scichilone N; Valenti G; Bonavita O; Andaloro S; Morini P; Rizzi A; Pelaia G
    Expert Rev Respir Med; 2022 Feb; 16(2):183-195. PubMed ID: 34845963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.
    Pascoe S; Reynolds C; Pleskow W; Perry S; Hmissi A; Kaiser G; Brookman L
    Int J Clin Pharmacol Ther; 2011 Feb; 49(2):153-61. PubMed ID: 21255532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP; Gallo O; Ritrovato D; Pradelli L
    Clin Drug Investig; 2021 Sep; 41(9):785-794. PubMed ID: 34333742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.